Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.
Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap.
Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...
Exact Sciences: Q3 Sell-Off May Be Unjustified, But Long-Term Outlook A Concern
Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...
Exact Sciences Announces Third-Quarter 2024 Results
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...
Exact Sciences Corporation (EXAS) Rebounded from the Previous Quarter
Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...
Exact Sciences Poised for Recovery and Long-Term Growth Amidst Challenges
Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday. Puneet Souda’s ...
Exact Sciences: Long-Term Growth Prospects Intact Despite Short-Term Challenges
Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...
Exact Sciences (EXAS) Q3 2024 Earnings Call Transcript
At this time, I would like to welcome everyone to the Exact Sciences third-quarter 2024 earnings conference call. [Operator ...
Madison-based Exact Sciences reports Q3 results short of analysts’ expectations
The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment ...
Investing7d
Exact Sciences stock target cut by Benchmark, retains Buy rating
On Wednesday, Benchmark analyst Bruce Jackson revised the price target on shares of Exact Sciences (NASDAQ:EXAS), reducing it to $65 from the previous $67, while reiterating a Buy rating on the stock.